
EpimAb Biotherapeutics to Present Initial First-in-human Data of EMB-02 at the 2023 ESMO Conference
SHANGHAI, China–(BUSINESS WIRE)–EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce that the company will present […]













